# A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Study · id `cardio:ct-nct02111564` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02111564](<https://clinicaltrials.gov/study/NCT02111564>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02111564

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 12024 participants.

## Technical summary

Registry record NCT02111564. Randomized; double masking; primary purpose prevention. Start 2014-01-07 (actual); primary completion 2018-03-06 (actual). Results posted on 2019-11-25.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 12024 participants (enrolled count; ClinicalTrials.gov record NCT02111564, source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)
- Started: 2014-01-07 (actual) (ClinicalTrials.gov record NCT02111564, source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)
- Primary completion: 2018-03-06 (actual) (ClinicalTrials.gov record NCT02111564, source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)
- Completion: 2018-05-03 (actual) (ClinicalTrials.gov record NCT02111564, source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)
- Results first posted: 2019-11-25 (ClinicalTrials.gov record NCT02111564, source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belarus; Bosnia & Herzegovina; Brazil; Bulgaria; Canada; Colombia; Croatia; Czechia; Denmark; Estonia; Georgia; Germany; Greece; Hungary; Israel; Latvia; Lithuania; Mexico; Netherlands; North Macedonia; Peru; Poland; Portugal; Puerto Rico; Romania; Russia; Serbia; Slovakia; South Africa; Spain; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02111564, source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02111564-2019-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
- Acronym: MARINER
- Condition: Heart Failure
- Condition: Respiratory Insufficiency
- Condition: Stroke Acute
- Condition: Infectious Diseases
- Condition: Rheumatic Diseases
- Intervention (Drug): Rivaroxaban, 10 mg
- Intervention (Drug): Rivaroxaban, 7.5 mg
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (`cardio:pubmed-30145946`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients (`cardio:pubmed-32586587`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness (`cardio:pubmed-36205248`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9c53521ec43cbd92e54370e8dd59bc920ff74d09e80e1b1312f76376f0352bcd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
